Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efepoetin Alfa in ND-CKD Anaemia
NCT04155125Phase 3Completed
- Sponsor
- Kalbe Genexine Biologics
- Start
- Jul 2020
- Primary completion
- Mar 2022
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 7
01
Overview
A Phase 3 trial of epoetin alfa in anemia of chronic kidney disease (CKD-A), sponsored by Kalbe Genexine Biologics. Started Jul 2020; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT04155125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04155125.